INTRODUCTION
============

Vitamin D represents one of the four liposoluble vitamins in our body that has the ability to synthesise in the skin under the influence of ultraviolet (UV) radiation. It consists of two bioequivalent forms that are biologically inert and thus must be activated by undergoing a process of double hydroxylation in the liver and kidneys ([@r1]). Calcidiol (25-hydroxy-vitamin D) is an active form of vitamin D that circulates in the blood linked to globulin as a product of hydroxylation in the liver. Consequently, measuring concentrations of calcidiol is the optimal way to properly determine vitamin D status in our body. Biological half-life of calcidiol is 14 days and its normal concentration in blood is 75--150 nmol/L. Concentrations less than 75 nmol/L indicate vitamin insufficiency, while its deficiency is considered when the concentrations are less than 50 nmol/L ([@r2]).

The most important role of vitamin D is to regulate absorption and homeostasis of calcium. In kidneys, calcidiol converts to calcitriol (1,25-hydroxy-vitamin D) after second hydroxylation process, and this bioequivalent form increases the absorption of calcium in the small intestine, while at the same time decreases the secretion of calcium by stimulating its resorption in distal renal tubules. Furthermore, calcitriol mobilises bone minerals so hypovitaminosis leads to osteomalacia in elderly (especially women) or rickets in young children ([@r3]). Only 15% of dietary calcium and approx. 60% of phosphorus are absorbed without vitamin D; conversely, its sufficiency raises calcium and phosphorus absorption by up to 40 and 80%, respectively ([@r4], [@r5]).

Production of vitamin D is influenced by UV radiation and exposure of the skin to sunlight. Therefore, skin is the main locale where its synthesis takes place. Areas above 40 degrees of south and north geographical latitude have low UV radiation, especially during winter time. Accordingly, people living in these areas are at greater risk of developing hypovitaminosis D (or vitamin D deficiency). Valuable source of vitamin D is food, especially fish oil (such as tuna, salmon and cod fish); however, since the intake of vitamin D with food satisfies only 20% of total daily needs, it is important to educate people on the importance of introducing foods rich in vitamin D in their quotidian meal plans ([@r6]).

As a steroid hormone, vitamin D binds to nuclear receptors and regulates expression of many genes (approx. 200) that in turn facilitate various pleiotropic health benefits reported for vitamin D ([@r7]). It has a wide range of effects -- from insulin secretion regulation to immune system modulation -- making it more similar to hormones than other vitamins ([@r8], [@r9]). Vitamin D has been implicated in a pathogenesis of various diseases such as diabetes type I, hypothyroidism, multiple sclerosis, systemic sclerosis and inflammatory bowel diseases (Crohn's disease and ulcerative colitis). Studies have also demonstrated anticancer activity of vitamin D, with quite a strong correlation between higher dose of calcidiol and lower incidence of colorectal carcinoma ([@r10]). Spending reasonably more time in the sun and using dietary vitamin D may prevent or even treat a plethora of malignomas (such as colorectal, breast, prostate or oesophageal cancers). Therefore, it is reasonable to expect higher usage and prescription of vitamin D supplementation in the near future ([@r11]), and there could also be a rationale for vitamin D food fortification. The aim of this review is to assess whether such approaches could be beneficial for our gut microbiota, and whether they exhibit therapeutic effects in patients affected by inflammatory bowel diseases (IBD).

VITAMIN D STATUS
================

Studies have generally shown insufficient concentration of vitamin D in the population around the globe; it can be said that its deficiency affects 40--50% of the populace ([@r12]). There are several risk factors that contribute to this issue of epidemic proportions. As we have already mentioned earlier, sunlight exposure and UV radiation affect the synthesis of vitamin D in the skin. Due to this reason alone we can expect lower concentrations in areas with less sunlight during the year, especially in the winter and early spring period. Large meta-analysis in Saudi Arabia showed that 60% of population have deficiency of vitamin D -- despite the fact this country has plenty of sunlight ([@r13]). Another risk factor is the type of skin. Darker pigmented skin contains more melanin, which acts as a natural protection from UV-B radiation. On the other hand, elderly individuals have thinner skin and lack 7-dehydrocholesterol, which is the main precursor of vitamin D ([@r14]).

Obese individuals and those with higher percentage of fat tissue are also prone to greater risk of hypovitaminosis. Nimri's ([@r15]) study on the population of female college students aged 18--26 recorded high frequency of vitamin D insufficiency in overweight and obese persons. A plausible explanation should be the enhanced uptake of vitamin D by adipose tissue; however, study suggests more complex and multifaceted relationship ([@r15]). Furthermore, pregnant women and women who are breast feeding for a long time are at higher risk of developing vitamin deficiency. Due to the fact that hypovitaminosis occurs in both genders, we can safely assume that external factors play a major role ([@r16]). Patients with malabsorption or other gastrointestinal (GI) diseases are at greater risk, thus preventive usage of vitamin D is advised.

Europeans (including Scandinavian citizens) have the highest concentrations of vitamin D in the world ([@r17]). Different sunlight exposure, dietary intake or use of vitamin D supplements may result in such favourable landscape. However, there are some 'gaps' on this map. In the northern parts of Italy researchers have identified 51.3% postmenopausal women with vitamin D insufficiency showing seasonal variations, the highest during winter-spring season ([@r18]). Croatia as a central European country also revealed some differences. Study conducted by Laktasic-Zerjavic *et al.* ([@r19]) showed that 92.5% of postmenopausal women, initially screened for osteoporosis, had inadequate vitamin D status. Additionally, hypovitaminosis D is a major problem in Croatia affecting entire population, not only risk groups (*e.g.* elderly or postmenopausal women). More than 80% of healthy young males have inadequate vitamin D status, which could have significant long-term negative effects on health ([@r20]).

Generally speaking, vitamin D deficiency is more prevalent than previously thought. The Centers for Disease Control and Prevention (CDC) have shown that vitamin D sufficiency (defined by 25-hydroxy-vitamin D of at least 30 ng/mL, which is a very vague criterion) has basically halved -- from 60% in Caucasian and 10% in African Americans during 1988--1994, to approx. 30% in Caucasians and 5% African Americans during 2001--2004 ([@r21]). Additionally, severe vitamin D deficiency has been demonstrated in a higher percentage of individuals ([@r21]). Moreover, even when more conservative approach to vitamin D deficiency is used, a large number of patients encountered in clinical practice may be deficient in vitamin D ([@r22]). Even though risk factors for vitamin D deficiency are well known, it seems that the condition has increased over time -- despite fortification of food in some countries (such as USA). The condition can be aggravated by decreased sunlight exposure, decreased oral intake and/or intestinal absorption of vitamin D in patients with IBD ([@r6], [@r16]). Furthermore, one of the potential explanations is an increased awareness of this deficiency, which is why some practitioners test for vitamin D deficiency even in low-risk patients ([@r23]).

Nonetheless, it has been proposed that clinicians should pursue routine testing for hypovitaminosis D in patients with musculoskeletal symptoms, most notably myalgias, bone pain, and generalised weakness ([@r22]). This review aims to suggest that the same approach may be considered for patients with significant gastrointestinal symptoms as well.

VITAMIN D FOOD SOURCES AND SUPPLEMENTS
======================================

The important source of vitamin D is food ([@r8]). If there is inadequate exposure to sunlight, it is pivotal to provide additional source of vitamin D to satisfy the needs of our body. However, since vitamin D is unstable at higher temperatures, fat-soluble and relatively complex molecule, there are certain challenges in analysing its exact concentration in food products. More specifically, this attempt necessitates food matrix digestion and concomitant extraction from fat-soluble components, extract clean-up and also a concentration step before the detection can be pursued. Analytical methods utilized to examine vitamin D in various foods include high pressure liquid chromatography (HPLC) and detection by ultraviolet absorption, mass spectrometry or a diode array detector ([@r24]). Currently used methods are all markedly similar, thus a demonstrated-performance method is used to assess their suitability (rather than defining a standard method) ([@r24]).

What we do know is that seafood, fish and eggs contain the highest concentration of vitamin D. Consequently, 100% of vitamin D total daily needs can be covered by eating 100 g of salmon, cod fish or mackerel ([@r25]). These species also contain significant amount of omega-3 fatty acids; however, long-living fish like tuna or salmon contain higher concentrations of mercury and other heavy metals, so the consumption should be cautiously moderate. Nowadays, fish liver oil can be found in the capsule form as one of the richest sources of vitamin D ([@r25]). Other nutrients containing vitamin D are milk, yogurt, egg yolks, shiitake mushrooms, cereals, oatmeal, fortified tofu, cheese, *etc.* Unfortunately, despite the variety of food that contains vitamin D, intake by food is still very poor -- therefore, educating people about healthy fats and promoting Mediterranean diet can be appropriate steps towards solving this problem.

Until then, dietary supplements are often considered as a 'quick fix', and 'total vitamin D intake' always reflects the joint dietary contribution from food sources and supplements ([@r8]). Such supplements are usually available in the form of pill, tablet, capsule, or some other controlled dosage form. Vitamin D present in them can be in either vitamin D2 or vitamin D3; however, the former is rarely used as the fortificant in dietary supplements ([@r26]). The reason is that vitamin D3 shows approx. 87% more potency for raising (and maintaining) concentrations of 25(OH)D in the serum and results in 2--3 times more storage of vitamin D than equimolar concentrations of vitamin D2 ([@r27], [@r28]).

Recommended Dietary Allowance (RDA), which is a measure that aims to reflect an average level of dietary intake per day that is deemed sufficient for meeting nutrient requirements for vitamin D in basically all healthy individuals, varies depending on the age. Thus RDA is 400 international units (IU) or 10 μg in male and female infants (*i.e.* younger than 1 year of age), 600 IU or 15 μg in all male and female individuals from 1 to 70 years of age, and 800 IU or 20 μg in those older than 70 years of age ([@r8]). It must be noted that, albeit sunlight may be considered a major source of vitamin D for certain people, RDAs of this vitamin are established on the premise of minimal sun exposure.

FOOD FORTIFICATION WITH VITAMIN D
=================================

Fortifying foods with vitamin D is still not a very pervasive practice around the world. The United States and Canada have previously fortified food with vitamin D2 ([@r29]), and today in the US and European Union either vitamin D2 or vitamin D3 can be used ([@r24]). In countries where food fortification with vitamin D is permitted, foods such as margarine, milk products and breakfast cereals have become staple contributors to vitamin D intake ([@r24]). Nonetheless, there is limited data in the literature regarding technological issues of food fortification with vitamin D.

Generally, fortification can be accomplished in different ways with variable efficiency. As mentioned before, in its native form vitamin D is fat soluble, although it can be prepared in water-soluble forms (*e.g.* emulsions) ([@r24]). Thus, adding vitamin D3 to cheese can be achieved by the addition of a commercial emulsion soluble in water, the addition of water-soluble vitamin D in multilamellar liposomes, or by the homogenisation of liposoluble crystalline vitamin D in a cream portion used for the standardisation of milk for cheese production ([@r30]). As only small amounts of vitamin D are necessary to meet nutrient requirements (for example, a suitable intake of vitamin D in adult women is 0.005 mg/day in comparison to 7 mg/day of vitamin E), low concentrations are added to foods -- hence, ensuring sample homogeneity can be rather difficult ([@r24]).

Wagner *et al.* ([@r31]) have shown that vitamin D3 is quite stable during cheese processing and after more than one year of ripening at the temperature between 3 and 8 °C. Approximately half of vitamin D3 supplemented to the milk for cheese production is subsequently bound in the whey and, thus, inaccessible for human biological processes. The added vitamin D3 is homogeneously distributed in cheese ([@r31]), and no loss is observed during fortified processed cheese manufacture or following storage for 9 months at 4--6 °C or 21--29 °C ([@r32]). Similar characteristics are seen for Cheddar cheese fortified with vitamin D3, where the added vitamin is stable over 9 months of storage, while consumer tests show that the fortified product is as acceptable as the unfortified one ([@r33]).

Regarding the heat stability of fortified products, heating of processed vitamin D3-fortified cheese for 3--5 min at 232 °C results in 25--30% vitamin loss ([@r32]). However, by applying the same conditions (*i.e.* heating for 5 min at 232 °C) or heating for 12 min at 100 °C, there is no loss of vitamin D3 observed in fortified low-fat or Cheddar cheese ([@r31]). Light can also be an issue; vitamin D3-fortified and heat-treated low-fat milk stored in clear polyethylene terephthalate (PET) containers can lose up to 66% of vitamin D3 during 12-week period; however, increasing the pigmentation level in the PET formulation may decrease that loss to 35% ([@r34]). Conversely, samples stored in the dark had a constant concentration of vitamin D3. In model systems, light-induced oxidation rate of vitamin D2 can be increased by riboflavin ([@r35]); on the other hand, by including microencapsulated lycopene in skimmed milk, riboflavin-mediated photodegradation of vitamin D3 can be decreased by 45% ([@r36]).

Taking all the aforementioned biotechnological issues into account, experience from European countries shows us that food fortification with vitamin D can be a relevant strategy to address the issue of its deficiency on a population level. In Finland, vitamin D fortification of fat spreads and fluid milk products in a systematic way started in 2003 to improve vitamin D status ([@r37]). The study that investigated the effects of such policy on vitamin D status in this population found significant improvements during the study period between 2000 and 2011 ([@r37]). In a population of Danish women with low vitamin D intake, low-dose vitamin D fortification of various foods has been touted as safe and effective population-based approach by Grønborg *et al.* ([@r38]). Similarly, vitamin D fortification of wheat flour has been shown as a viable option for securely improving vitamin D intake and the overall status of various population groups at risk of deficiency in the United Kingdom -- without increasing the risk of surpassing present reference thresholds ([@r39]).

Some researchers caution how creative food-based solutions are increasingly warranted to bridge the gap between current intake and required values of vitamin D, highlighting biofortification of wider range of foods ([@r40]). In short, food fortification with vitamin D has been touted as a possibly optimal way to increase intake due to its widest reach and population impact.

MICROBIOTA AND VITAMIN D
========================

Gut microbiota consists of a large number of various bacterial species that are fluctuating during human lifetime ([@r41]). Even though bacterial colonisation begins at birth, nutrition and lifestyle choices dictate its final composition. Fibre, as final product of digestion, is necessary for the production short-chain fatty acids (SCFAs) by bacteria residing in the gut. SCFAs (propionate, butyrate, or acetate) show a plethora of modulatory effects on the gastrointestinal system and metabolism ([@r42]). The connection between gut and brain is well established, and it shows that SCFAs contribute to the synthesis of many neurotrasmitters. The most representative bacteria in gut microbiota are *Bacteroidetes* and *Firmicutes*, with higher ratio of *Bacteroidetes*. Vegan nutrition, rich in indigestible fibre (such as inulin and galactooligosaccharides), favours the growth of *Bacteroidetes*; on the other hand, Western food full of refined carbohydrates and saturated fatty acids favours the growth of *Firmicutes* ([@r43]).

With its immunomodulatory role and the production of anti-inflammatory factors, vitamin D also exerts influence on the gut microbiota. Vitamin D receptor (VDR) is expressed on the intestinal epithelial cells, and it seems that SCFA butyrate increases its expression even more ([@r44]). Vitamin D is important for maintaining intestinal barrier integrity, thus its deficiency leads to dysbiosis and potential translocation of gut bacteria ([@r45]). The efficiency of vitamin D depends on the concentration and the ability of binding to VDR. Furthermore, the production of bile acids is increased by regular consumption of Western diet, which can adversely affect the availability of vitamin D in the gut; in addition, microbial disturbances are often coupled with alterations in bile acid profiles of the host ([@r46]). More specifically, bile acids (like cholic and lithocholic acid) are ligands for VDR and, when bound to VDR, have the propensity to decrease the availability of vitamin D ([@r43]). A purported strong impact of vitamin D on the gut microbiota initiated studies about possible connection between maternal vitamin D status and newborn bacterial colonisation of the intestinal tract. Maternal supplementation of vitamin D and breast feeding the infants resulted in lower burden of *Clostridium difficile* ([@r47]), which is a hazardous bacterial species that may give rise to pseudomembranous colitis and potentially fatal necrotizing enterocolitis in newborns.

A recent cross-sectional analysis from Brazil showed that systemic inflammation markers are highly dependent on the relationship between the composition of gut microbiota and the concentration of vitamin D ([@r48]). In this study, *Prevotella* species were more abundant, while *Veillonella* and *Haemophilus* species were less abundant in the subset of patients characterised by the highest vitamin D intake ([@r48]). Kanhere *et al.* ([@r49]) went one step further and conducted a randomized, double-blind, placebo-controlled clinical trial that aimed to assess gut and airway microbiota of patients with cystic fibrosis based on their vitamin D status. This study has shown differential gut microbiota composition in patients with vitamin D insufficiency after 12-week long treatment with either vitamin D3 or placebo, with *Lactococcus* numbers significantly higher in the former (*i.e.* vitamin D3) group, and *Erysipelotrichaceae* and *Veillonella* more common in the latter (*i.e.* placebo) group ([@r49]). Furthermore, in an interventional pilot study, Bashir *et al.* ([@r50]) showed how vitamin D3 has the ability to modulate the microbiome of the upper GI tract, with increased bacterial richness and decreased abundance of *Gammaproteobacteria.* All these data demonstrate that vitamin D can indeed regulate the gut microbiome and that either vitamin D or VDR deficiency may result in dysbiosis, opening the door for subsequent gut injuries and an array of different diseases.

INFLAMMATORY BOWEL DISEASES AND VITAMIN D
=========================================

IBD can be seen as an umbrella term for idiopathic, relapsing and remitting inflammatory diseases of gastrointestinal tract which include Crohn's disease (CD) and ulcerative colitis (UC) ([@r51]). The aetiology of IBD is multifactorial, but it is in part due to the deregulation of the immune response to various environmental factors, coupled with a pre-existing genetic predisposition ([@r52]). Both diseases commonly affect young people as a result of aberrant mucosal immune response in genetically susceptible individuals. In Croatia the incidence of UC and CD is 4.3/100 000 and 7/100 000, respectively ([@r53]). There are many risk factors affecting IBD, but smoking is the only one proved with a sort of two-faced effect, increasing the risk for CD and reducing the risk for UC ([@r54], [@r55]). In CD a transmural granulomatosis inflammation can be found in any part of GI system, although in 70% cases terminal ileum is affected. On the other hand, UC affects colonic mucosa and in a majority of cases causes proctitis ([@r56]). Both diseases manifest with episodic or chronic diarrhoea, crampy abdominal discomfort and systemic symptoms (fever, mass loss and/or malaise) ([@r56]). If there is a mixed group of abdominal symptoms without any organic cause, and all other diseases are excluded, we can diagnose irritable bowel syndrome (IBS). When the inflammation affects microvilli, there is a reduced ability of absorption in the intestine. Malabsorption in patients with IBD almost invariably leads to hypovitaminosis D. Large studies have shown that more than 60% of patients with IBD have inadequate concentration of vitamin D ([@r57]). When compared to healthy population without IBD, the prevalence of hypovitaminosis is quite similar to patients with IBD. Also, it has been shown that solar UVB exposure reduces risk of IBD based on results from ecological studies ([@r58], [@r59]). Hence we pose the question -- is it possible that hypovitaminosis D triggers IBD, or is it only a secondary result of the disease?

Plenty of different research endeavours aimed to answer that pertinent query. From an immunological perspective, vitamin D regulates the immune system and calcitriol appears to play a role in the development of self-tolerance. It decreases Th1-driven autoimmune response by regulating T helper cell and dendritic cell function ([@r60]). Th1 autoimmune response represents the main inflammation pathway in patients with CD, while Th1 cells produce proinflammatory cytokines (including IFN-γ, IL-2 and TNF-α). *In vitro* studies with calcitriol show the important role in reducing the production of proinflammatory cytokines and promoting T helper/Th2 regulatory responses to produce anti-inflammatory interleukin (IL)-4. Patients with UC have suppressed Th2 inflammatory response in general, while evidence points to a plethora of beneficial effects on the gut immune system ([Table 1](#t1){ref-type="table"}; ([@r61])). Strong *in vitro* evidence of immunomodulatory vitamin D effects instigated human studies with vitamin D supplements in IBD, which have shown that vitamin D supplementation in IBD patients improves inflammatory bowel disease outcomes by inducing or maintaining remission, and improving quality of life scores ([@r62]).

###### A summary of physiological effects of vitamin D on the gut immune system according to Gubatan and Moss ([@r61]); reduced levels of vitamin D can affect all of the functions

      ▪ Protection of the integrity of the intestinal epithelial barrier
  ------------------------------------------------------------------------------------------
      ▪ Reduced epithelial cell injury induced by *Escherichia coli* or lipopolysaccharide
      ▪ Differential regulation of intestinal tight junction proteins
      ▪ Suppression of gut epithelial cell apoptosis
      ▪ Stimulation of NOD2/CAR15 expression
      ▪ Increase in antimicrobial peptides such as defensins and cathelidicin
      ▪ Proliferation control of CD8^+^ T cells involved in intestinal inflammation
      ▪ Inhibition of proinflammatory Th1 and Th17 cells
      ▪ Down-regulation of interleukin-23 receptor pathway
      ▪ General promotion of intestinal immune tolerance

It must be noted that clinical trials in humans that have interrogated the role of vitamin D axis in IBD are regularly heterogeneous regarding their overall design and methods used, hampering in turn the comparability of research findings ([Table 2](#t2){ref-type="table"}; ([@r51]-[@r55], [@r57], [@r58])). Still, most of those studies share common points of agreement on the benefits of vitamin D supplementation regarding disease outcomes and achieved quality of life ([@r63]). For example, randomized trials on CD patients have shown that high doses of vitamin D3 supplementation (up to 10 000 IU per day) may substantially decrease clinical relapse rates ([@r64], [@r65]), and some other studies even hinted how vitamin D supplementation (particularly in its active form) may result in short-term beneficial impact on disease activity ([@r66]). Similar results were found in patients with UC, where vitamin D supplementation (especially in high doses) resulted in diminished disease activity, better scores assessing symptom-based activity, as well as significantly improved quality of life ([@r67], [@r68]). Suboptimal levels of 25-hydroxy-vitamin D in circulation are frequently seen in IBD and are associated with the risk of flairs, inadequate response to drugs, more common hospitalisations and surgeries, low bone mineral density, as well as deterioration of life quality ([@r56]). This is also substantiated by a very recent study where many researchers addressed vitamin D deficiency in a European IBD inception cohort (also known as Epi-IBD study) ([@r69]). In a total of 238 patients that were recruited between 2010 and 2011, they demonstrated high prevalence of vitamin D deficiency in treatment-naive European populations with IBD, and also highlighted low vitamin D levels in patients who smoke. Such large efforts may open the door to consider food fortification with vitamin D as a viable strategy.

###### Summary of clinical trials where vitamin D is used in the treatment of inflammatory bowel diseases (IBD) (as discussed in this review)

  Type                                                                 *N*(patient)   Intervention                                                                              End-result                                                                                                                  Reference
  -------------------------------------------------------------------- -------------- ----------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------- -----------
  Randomized, double-blind, placebo-controlled trial                   108            1200 IU of oral vitamin D3 *vs* placebo                                                   Non-significant reduction of Crohn's disease relapse risk                                                                   ([@r51])
  Randomized, double-blind, placebo-controlled trial                   32             10 000 IU D3 *vs* 1000 IU of oral vitamin D3                                              Significant reduction of Crohn's disease relapse risk only in per-protocol analysis                                         ([@r52])
  Prospective clinical trial                                           37             Active form of vitamin D *vs* plain form of vitamin D                                     Significant reduction of Crohn's disease activity index and C-reactive protein                                              ([@r53])
  Randomized, double-blind, prospective trial                          18             2000 IU *vs* 4000 IU of oral vitamin D3                                                   No significant improvement in the quality of life in patients with ulcerative colitis                                       ([@r54])
  Prospective pilot study                                              10             Oral liquid vitamin D supplementation (5000 IU in 1 mL)                                   Improved symptom-based IBD activity scores, but no improvement in objective measures of intestinal/systemic inflammation    ([@r55])
  Prospective, longitudinal, controlled interventional trial           17             380 000 IU of vitamin D (25-OH) in patients with Crohn\'s disease *vs* healthy controls   Significant change in microbial community composition in patients with Crohn's disease                                      ([@r57])
  Prospective, longitudinal, placebo-controlled interventional trial   19             1200 IU of oral vitamin D3 + calcium *vs* just calcium                                    Significantly reduced monocyte-derived dendritic cell maturation and cytokine production in patients with Crohn's disease   ([@r58])

A shift of the composition of intestinal microbiota is probably implicated in adverse disease outcomes as well. For example, in a recent prospective controlled interventional study in Germany, Schäffler *et al.* ([@r70]) showed that the microbial communities found in CD patients were significantly altered during early vitamin D administration when compared to healthy controls. By analysing highly abundant species, they concluded that the vitamin D supplementation may be a harbinger of positive effects in CD -- not only by modulating intestinal bacterial flora, but also by expanding the abundance of potentially beneficial bacterial species ([@r70]). Such microbial perturbations are supplemented by beneficial immune modulation that is also prompted by vitamin D supplementation; for example, it has been shown that vitamin D3 in CD patients may reduce cytokine production (most notably IL-1β, IL-6 and IL-10) and monocyte-derived dendritic cell maturation ([@r71]). Although the optimal protocol of vitamin D supplementation in patients with IBD is still not straightforward, recommended blood concentrations of vitamin D in this population are between 75 and 125 nmol/L, with daily doses ranging between 1800 and 10 000 IJ ([@r6]). These values proved to be safe and beneficial in active forms of the disease.

CD and UC cannot be considered diseases of vitamin D deficiency *sensu stricto*; however, their pathogenesis is evidently closely related to vitamin D at cellular and phenotypic levels. Due to the complex relationship of vitamin D and IBD, it is extremely hard to unequivocally establish causation, and for more significant results future intervention trials should include larger cohorts of patients. For now, both theoretical and empirical support is solid enough to claim vitamin D indeed plays a substantial role in ameliorating disease parameters in patients with CD and UC ([Table 2](#t2){ref-type="table"}). It is thus of utmost importance to focus on adequate vitamin D levels during asymptomatic periods of the disease in further interventions, while at the same time investigate potential synergistic effects with present and future treatment modalities. Regarding the latter, it should be emphasised that vitamin D3-containing nanostructured lipid carriers have already been explored as an alternative mode of treating IBD ([@r72]). Additional treatment approaches at the microbiome level represent promising opportunities towards balanced gut microbiota and improved IBD symptoms ([@r73]).

CONCLUSIONS
===========

Vitamin D in immune-mediated disorders seems to be closely linked to bacterial composition and their metabolism, as chronic intestinal dysbiosis in compromised conditions may cause vitamin D receptor dysfunction and thus trigger a vicious cycle that finally results in diseased state. A growing base of evidence supports the concept of intricate relationship between gut dysbiosis and vitamin D metabolism, which holds the potential of discovering new pathogenic mechanisms and increasing treatment options at our disposal. The research has shown how vitamin D insufficiency can be associated with gut microbiota alterations that may boost inflammation processes; therefore, impacting microbial composition with vitamin D supplementation may bring substantial benefits to the affected individuals. For now, there are still some gaps that prevent the inclusion of recommendations on manipulating vitamin D axis and gut microbiome into the guidelines for clinical practice; however, recent research is quite encouraging in instituting higher doses of vitamin D as one of the complementary approaches to our therapeutic armamentarium in IBD. In conclusion, although the answer to the question whether there is a therapeutic and preventive potential of vitamin D supplementation and food fortification in patients with CD and UC is still not straightforward, it is steadily moving towards a favourable 'yes'.
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